Meeting Coverage:

American Academy of Ophthalmology

AAO: 2019

A New Anti-VEGF Option

Show Description +

J. Fernando Arevalo, MD, PhD, FACS, explains the indication for brolucizumab (Beovu, Novartis) and details the findings from the parallel phase 3 HAWK and HARRIER trials, which evaluated brolucizumab in patients with wet age-related macular degeneration.

Posted: 10/23/2019

Up Next


PANORAMA Study Data

Rishi P. Singh, MD

Gene Therapy for Wet AMD

Szilard Kiss, MD

ABC to Block VEGF-A Isoforms

Charles C. Wykoff, MD, PhD

Surgery for Viral Retinitis

J. Fernando Arevalo, MD, PhD, FACS

Iridocorneal Endothelial Syndrome

Lauren S. Blieden, MD

Advanced Diagnostics in Refractive Surgery: Epithelial Mapping and Phakic IOL Sizing

Dan Z. Reinstein, MD, MA(Cantab), FRCSC, DABO, FRCOphth, FEBO

Efficacy of Presbyond for the Correction of Presbyopia

Dan Z. Reinstein, MD, MA(Cantab), FRCSC, DABO, FRCOphth, FEBO

Autonomous AI in Ophthalmology

Michael D. Abramoff, MD, PhD

CXL for Infectious Keratitis

Farhad Hafezi, MD, PhD, FARVO

MIGS and Medications

Alex Huang, MD

Controlling Wound Healing Following PRK

Farhad Hafezi, MD, PhD, FARVO

A New Anti-VEGF Option

J. Fernando Arevalo, MD, PhD, FACS, explains the indication for brolucizumab (Beovu, Novartis) and details the findings from the parallel phase 3 HAWK and HARRIER trials, which evaluated brolucizumab in patients with wet age-related macular degeneration.

Posted: 10/23/2019


Please log in to leave a comment.

More From AAO: 2019 Coverage